Zymeworks Inc. (ZYME)
NASDAQ: ZYME
· Real-Time Price · USD
18.62
0.39 (2.14%)
At close: Oct 15, 2025, 3:59 PM
18.62
0.00%
After-hours: Oct 15, 2025, 04:20 PM EDT
2.14% (1D)
| Bid | 18.23 |
| Market Cap | 1.4B |
| Revenue (ttm) | 122.87M |
| Net Income (ttm) | -73.67M |
| EPS (ttm) | -0.98 |
| PE Ratio (ttm) | -19 |
| Forward PE | -20.12 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 19.75 |
| Volume | 524,295 |
| Avg. Volume (20D) | 538,818 |
| Open | 18.35 |
| Previous Close | 18.23 |
| Day's Range | 18.07 - 18.69 |
| 52-Week Range | 9.03 - 19.50 |
| Beta | 1.51 |
| Ex-Dividend Date | n/a |
About ZYME
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ZYME
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ZYME stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsZymeworks Inc. is scheduled to release its earnings on
Oct 30, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-5.4%
Zymeworks shares are trading lower after the compa...
Unlock content with
Pro Subscription
7 months ago
-7.97%
Zymeworks shares are trading lower after the company reported worse-than-expected Q4 financial results.
1 month ago · seekingalpha.com
Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press OnI maintain my Strong Buy rating on Zymeworks Inc., driven by its robust ADC pipeline and upcoming pivotal zanidatamab data in late 2025. ZW171 was discontinued due to on-target off-tumor toxicity, but...
